Danavorexton - Takeda
Alternative Names: TAK-925Latest Information Update: 09 Dec 2025
At a glance
- Originator Takeda
- Class Cyclohexanes; Esters; Ethers; Piperidines; Sleep disorder therapies; Small molecules; Sulfonamides
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Yes - Narcolepsy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Respiration disorders
- No development reported Idiopathic hypersomnia
- Discontinued Narcolepsy; Neurological disorders; Sleep apnoea syndrome
Most Recent Events
- 09 Dec 2025 Discontinued - Phase-I for Narcolepsy (In the elderly, In adults) in Japan (IV) (Takeda pipeline, November 2025)
- 09 Dec 2025 Discontinued - Phase-I for Narcolepsy (In volunteers) in USA (IV) (Takeda pipeline, November 2025)
- 25 Sep 2025 Discontinued - Phase-I for Sleep apnoea syndrome (In the elderly, In adults) in Australia (IV) (Takeda Pipeline, September 2025)